TargED Biopharmaceuticals picks up Series A

TargED Biopharmaceuticals, a developer of treatments for thrombotic diseases, has raised 39 million euros in Series A financing.

22 February 2022•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles